Stephanie Terezakis
Overview
Explore the profile of Stephanie Terezakis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
612
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mrvoljak M, Mishra S, Chen L, Neil E, Ehler E, Terezakis S, et al.
Front Oncol
. 2025 Feb;
15:1501466.
PMID: 39968069
Glioblastoma (GB) is a primary brain tumor that is lethal and challenging to treat. The 3-year overall survival (OS) of patients with this diagnosis has stayed the same since 2005....
2.
Wanhainen K, Berkseth M, Sando N, Golden L, Techam A, Wieworka J, et al.
Adv Radiat Oncol
. 2024 Dec;
10(2):101677.
PMID: 39703718
Purpose: The immunosuppressive function of myeloid-derived suppressor cells (MDSCs) has been implicated in the regulation of immune responses against cancer and is associated with poor prognosis. Radiation treatment is known...
3.
Oh J, Skinner L, Gutkin P, Jiang A, Donaldson S, Loo Jr B, et al.
Adv Radiat Oncol
. 2024 Sep;
9(10):101589.
PMID: 39309703
Purpose: The Audiovisual-Assisted Therapeutic Ambience in Radiotherapy (AVATAR) trial was a prospective multicenter study (NCT03991156) examining the combination of video immersion with radiation therapy and was successfully conducted through the...
4.
Song C, Kim H, Kim M, Park H, Paek S, Terezakis S, et al.
Cancer Res Treat
. 2024 Jun;
57(1):1-10.
PMID: 38853541
Tumor microenvironment is intrinsically hypoxic with abundant hypoxia-inducible factors-1α (HIF-1α), a primary regulator of the cellular response to hypoxia and various stresses imposed on the tumor cells. HIF-1α increases radioresistance...
5.
McCammack E, Terezakis S
Int J Radiat Oncol Biol Phys
. 2024 Jun;
119(3):718.
PMID: 38851269
No abstract available.
6.
Binkley M, Flerlage J, Savage K, Akhtar S, Steiner R, Zhang X, et al.
J Clin Oncol
. 2024 Mar;
42(19):2271-2280.
PMID: 38531001
Purpose: Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and immunoarchitectural patterns (IAPs) for...
7.
Weiss A, Chen Y, Scharschmidt T, Xue W, Gao Z, Black J, et al.
J Clin Oncol
. 2023 Jul;
41(31):4842-4848.
PMID: 37523624
JCO ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity...
8.
Jurdi N, Hoover A, OLeary D, Cao Q, Gupta A, Ebens C, et al.
Transplant Cell Ther
. 2023 Jun;
29(9):576.e1-576.e5.
PMID: 37311510
Graft-versus-host disease (GVHD) is the major toxicity of allogeneic hematopoietic cell transplantation (HCT). We hypothesized that a GVHD prophylaxis regimen of post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF)...
9.
Song C, Terezakis S, Park W, Paek S, Kim M, Cho L, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(3):701-704.
PMID: 37196835
No abstract available.
10.
Jurdi N, Hoover A, OLeary D, Cao Q, Gupta A, Ebens C, et al.
medRxiv
. 2023 Apr;
PMID: 37034603
Introduction: Graft-versus host disease (GVHD) is a major limitation to the success of allogeneic hematopoietic cell transplant (HCT). We hypothesized that the GVHD prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus...